当前位置: X-MOL 学术Lancet Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Neoadjuvant chemotherapy in oesophageal adenocarcinoma
The Lancet Oncology ( IF 51.1 ) Pub Date : 2017-11-01 , DOI: 10.1016/s1470-2045(17)30812-4
Hanneke W M van Laarhoven , Mark I van Berge Henegouwen , Maarten C C M Hulshof

We applaud Derek Alderson and colleagues1 for conducting the UK MRC OE05 trial. This randomised study showed that four neoadjuvant cycles of epirubicin, cisplatin, and capecitabine (ECX) did not improve survival of patients with oesophageal cancer compared with two neoadjuvant cycles of cisplatin and fluorouracil (CF).1 Thereby, this study contributes to the body of knowledge showing that anthracyclines have a limited role in systemic treatment of oesophagogastric cancer.2 However, we urge caution in the interpretation of this study confirming that two neoadjuvant cycles of CF is standard of care for patients with resectable oesophageal adenocarcinoma.

中文翻译:

食管腺癌的新辅助化疗

我们赞扬Derek Alderson及其同事1进行了英国MRC OE05试验。这项随机研究表明,与两个新的顺铂和氟尿嘧啶(CF)新辅助周期相比,表柔比星,顺铂和卡培他滨(ECX)的四个新辅助周期不能提高食道癌患者的生存率。1因此,这项研究为知识体系做出了贡献,表明蒽环类药物在食管胃癌的全身治疗中作用有限。2然而,我们在解释本研究时要谨慎,以确认CF的两个新辅助周期是可切除食管腺癌患者的标准治疗方法。
更新日期:2017-11-01
down
wechat
bug